Recent Company News

• 01:01 AM ET Jul 15, 2026
  

  FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy (CHF 327.00, 0.00)

• 08:27 PM ET Jun 30, 2026
  

  NICE recommends Lilly's pirtobrutinib to treat relapsed or refractory CLL after a BTK inhibitor ($1199.43, 0.00)

• 07:10 AM ET Jun 26, 2026
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Jaypirca ($1127.69, 0.00)

• 02:41 AM ET Jun 23, 2026
  

  MHLW grants orphan drug designation to Nippon Shinyaku's NS-035 for treatment of Fukuyama congenital muscular dystrophy (¥4016.0000, 0)

• 07:35 AM ET Jun 22, 2026
  

  REGENXBIO confirms alignment with FDA on path forward for NAVSUNLI BLA resubmission for accelerated approval; expects to resubmit the BLA in Q3 2026 ($7.80, 0.00)

• 04:54 AM ET Jun 14, 2026
  

  Eli Lilly presents results from BRUIN CLL-322 clinical trial of Jaypirca ($1133.00, 0.00)

• 11:05 PM ET May 14, 2026
  

  Nippon Shinyaku reports FY net income attributable ¥29.72B vs guidance 26.30B and FactSet ¥27.58B [6 est, ¥26.60-29.70B] (¥4200.0000, +83)

• 11:24 PM ET May 09, 2026
  

  Nippon Shinyaku downgraded to neutral from overweight at JPMorgan

• 05:06 PM ET May 07, 2026
  

  Capricor Therapeutics files lawsuit related to Commercialization and Distribution Agreement with Nippon Shinyaku - 8-K ($33.94, 0.00)

• 09:03 AM ET Apr 22, 2026
  

  Capricor announces late-breaking presentation of HOPE-3 Phase 3 results at the AAN 2026 Annual Meeting ($35.34, 0.00)